GlassScriptPhysician profile
Rose K Appel
NPI 1760757033
$566.68
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.11 · 2022: $31.05 · 2023: $327 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $332.24 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $45.24 | 2023 | Pifeltro, Dificid, Delstrigo |
| Sunovion Pharmaceuticals INC. | $41.12 | 2019 | |
| Glaxosmithkline, LLC. | $38.40 | 2023 | Bexsero, Pediarix |
| Novo Nordisk INC | $36.74 | 2023-2024 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $29.79 | 2019 | |
| Amgen INC. | $17.95 | 2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $13.44 | 2019 | |
| Pfizer INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Appel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.